AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a ...
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...
Atai Life Sciences (ATAI) this past Friday, July 25, 2025 reported results from its phase 2b study using its drug inidascamine for the treatment of patients with cognitive impairment associated with ...
Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 ...
NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Atai Life Sciences N.V. is one of them. Atai Life Sciences N.V. (NASDAQ:ATAI), headquartered in ...
Hosted on MSN
North Carolina Wants to ‘Lead the Nation’ in Psychedelics. Here’s 1 ‘Strong Buy’ Stock to Buy Now.
Depression remains one of the world’s most debilitating conditions, impacting millions worldwide with symptoms that can disrupt every facet of life — from work and relationships to basic daily ...
ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering.
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results